How to Read Peptide Evidence: Animal Studies vs Human Trials, Using BPC-157 as the Example — A Literacy Guide for Coaches and Curious Clients

This guide is for coaches and for clients across our US metros, from New York to Los Angeles, who keep seeing peptide claims on social media. It follows our previous explainers on the Federal Register notice and on "research use only" products, and focuses on a different skill: reading the evidence itself.

Research comes in layers. From weakest to strongest for answering "will this help a person like me?":

1. Cell (in vitro) studies. Useful for mechanisms; they can't tell you about real-world benefit or safety in people.
2. Animal studies. Rats, mice or rabbits with induced injuries. Doses, injury types and healing biology differ from humans.
3. Case reports and retrospective series. Real people, but no comparison group, so improvement may be natural healing, other treatment or expectation.
4. Randomised controlled trials (RCTs). People randomly assigned to the treatment or a control. The best way to test cause and effect.
5. Systematic reviews and meta-analyses of RCTs. Strongest, if the underlying trials are good.

A systematic review is only as good as what it reviews. A review of animal studies is still animal evidence.

• The 2025 orthopaedic systematic review (PubMed 40756949) included 36 studies: 35 preclinical and one clinical. The single clinical study was retrospective: 7 of 12 patients with knee pain reported relief lasting more than six months. With no control group and 12 people, that cannot separate the peptide from other causes. The review reported no clinical safety data.
• A 2025 narrative review, "Regeneration or Risk?" (Curr Rev Musculoskelet Med, PMC12446177), identified only three small human pilot studies and raised the possibility of publication bias, which is when positive results are more likely to be published than negative ones.

Plain-language summary for a client: "BPC-157 looks interesting in animal studies. In people, there's very little research, it's small and uncontrolled, and we don't have good safety data. That's a question for a doctor, not something to try from a website."

Regulation and evidence are different questions, and social media often blurs them.

• FDA approval means FDA reviewed evidence of safety and effectiveness for a specific use. You can check approved drugs at Drugs@FDA.
• FR 2026-22192 (Federal Register, 30 Oct 2026) is an interim 503A compounding enforcement-discretion policy covering six peptide bulk substances (BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c). It describes when HHS does not intend to take enforcement action against certain state-licensed pharmacy compounding under section 503A. It is not FDA approval and not the final bulks list, and it does not establish that any of these peptides is safe or effective.
• FDA has previously listed several of these substances on its page of bulk drug substances that may present significant safety risks, and the Pharmacy Compounding Advisory Committee met in July 2026 to discuss bulk substances. Check those pages for the current position rather than relying on a post.

So "a pharmacy may compound it under this interim policy" and "it works" are two separate claims. The first is about enforcement; the second needs evidence.

1. In whom? Cells, animals or people? How many people?
2. Compared with what? Was there a control or placebo group?
3. Measured how? Pain scores a person reports, or objective outcomes like imaging or function tests?
4. What about harms? Were side effects tracked, and for how long?
5. Who's telling me? Does the source sell the product, or earn from referrals?

If the answer to question 5 is "yes", look harder at questions 1 to 4.

A coach can:

• explain the difference between animal and human evidence
• explain what FR 2026-22192 does and doesn't mean, using the locked wording above
• help a client write down questions for their doctor
• keep coaching the basics that do have human evidence for recovery, such as progressive loading under a physiotherapist's plan, sleep and protein.

A coach never:

• recommends, doses, sources or sells a peptide
• points to a "research use only" seller
• tells a client a peptide is "FDA-approved" or "legal now".

Refer to a clinician if a client is already injecting a product, has symptoms at an injection site (redness, swelling, fever), or has an injury that isn't improving. With signs of a severe allergic reaction, call 911.

Client: "My friend healed her shoulder with BPC-157. Should I try it?"

Coach: "I'm glad she's better. Shoulders often improve with time and rehab, so it's hard to know what helped. The research on BPC-157 in people is very limited and there isn't good safety data. The recent HHS notice is about pharmacy compounding enforcement, not FDA approval. If you're curious, it's a good question for your doctor or sports medicine physician. Meanwhile, let's make sure your rehab plan from your physio is happening three times a week."

Our Level 5 post-injury stack request case works through this conversation in more depth.

Start free at Level 1. Level 3 (US$300): what peptides are and evidence quality for coaches. Level 4 (US$500): mechanisms of the six HHS-listed peptides and the HHS 503A peptide policy. Level 5 (US$500): hard cases. Education and referral, not a grey-market pharmacy. We do not guarantee income or client numbers.

This article is education, not medical advice. It does not recommend, endorse or provide any peptide. Talk to a licensed clinician about your own health.